A Promising Drug Target in Immunology: IGHD1-1 (Immunoglobulin Heavy Diversity 1-1)

Target Name: IGHD1-1

NCBI ID: G28510

IGHD1-1

Other Name(s): immunoglobulin heavy diversity 1-1 | IGHD11 | Immunoglobulin heavy diversity 1-1

A Promising Drug Target in Immunology: IGHD1-1 (Immunoglobulin Heavy Diversity 1-1)

Immunoglobulin heavy diversity 1-1 (IGHD1-1) is a protein that plays a crucial role in the immune system. It is a subunit of the immunoglobulin molecule, which is the most abundant protein in the bloodstream. IGHD1-1 is responsible for helping the immune system to recognize and respond to foreign substances like viruses and bacteria.

Unfortunately, IGHD1-1 has also been associated with several diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. Its role in these diseases has led researchers to investigate its potential as a drug target. In this article, we will explore the potential of IGHD1-1 as a drug target and discuss its potential clinical applications.

The IGHD1-1 Protein

IGHD1-1 is a 146-kDa protein that is expressed in a variety of tissues throughout the body. It is composed of four heavy chains and one light chain. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chain contains one variable (V) region and one constant (C) region.

IGHD1-1 has been shown to play a critical role in the immune response. It is one of the most abundant proteins in the immune system, making up around 20% of total protein in the bloodstream. It is involved in the development and maintenance of the antibody response, as well as in regulating the activation and proliferation of B cells.

In addition to its role in the immune system, IGHD1-1 has also been shown to play a critical role in the regulation of inflammation. It has been shown to reduce inflammation in various experimental models, including mouse models of autoimmune arthritis and diabetic inflammation.

Drug Target Potential

The potential of IGHD1-1 as a drug target comes from its unique structure and function. IGHD1-1 has a unique mechanism of post-translational modification, which allows it to be targeted by small molecules. This mechanism has led to the development of small molecules that can inhibit the activity of IGHD1-1 and enhance its sensitivity to chemotherapy.

One of the most promising small molecules that has been shown to interact with IGHD1-1 is 纬-secretase inhibitor (GSI), which is a drug that has been shown to enhance the sensitivity of cancer cells to chemotherapy in a variety of models.GSI has also been shown to inhibit the activity of IGHD1-1 and enhance its sensitivity to chemotherapy in a variety of models.

Another small molecule that has been shown to interact with IGHD1-1 is 2-phenyl-2-propanethiol (2-PPT), which is a drug that has been shown to inhibit the activity of IGHD1-1 and enhance its sensitivity to chemotherapy in a variety of models.

Clinical Applications

The potential of IGHD1-1 as a drug target has led to the development of several clinical applications. One of the most promising clinical applications is the use of IGHD1-1 as a biomarker for monitoring the effectiveness of cancer treatments.

IGHD1-1 has been shown to be a reliable biomarker for monitoring the effectiveness of chemotherapy in a variety of models. In one study, researchers found that IGHD1-1 levels were significantly reduced in response to chemotherapy, which suggests that IGHD1-1 may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Another promising clinical application of IGHD1-1 is the use of IGHD1-1 as a target for cancer immunotherapy. IGHD1-1 has been shown to play a critical role in the regulation of the immune response, and has been shown to enhance the

Protein Name: Immunoglobulin Heavy Diversity 1-1

Functions: D region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHD1-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHD1-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets